Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Marketed paracetamol · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Marketed paracetamol | ACTIVE_COMPARATOR | Marketed paracetamol |
| Experimental paracetamol formulation | EXPERIMENTAL | Experimental formulations |
| Name | Type | Description |
|---|---|---|
| Marketed paracetamol | DRUG | Marketed paracetamol |
| Experimental paracetamol formulation | DRUG | Experimental paracetamol formulation |
Inclusion Criteria: * Healthy male or female volunteers aged 18-55 years with a body mass index ranging from 19-28 kilograms per square meter who have given informed consent
Marketed paracetamol is used for pain. It is a small molecule medicine developed by GSK plc, which trades under the ticker GSK. The clinical program in pain includes one completed Phase 1 trial conducted in the United States.
Marketed paracetamol is developed by GSK plc, which trades under the ticker GSK. GSK is the sponsor associated with the clinical development program for this pain medicine.
Marketed paracetamol has been studied in Phase 1 clinical development. One Phase 1 trial has been completed, and no trials are currently active. The completed study enrolled 30 participants and was conducted in the United States.
Marketed paracetamol has been evaluated in one clinical trial, NCT01592227, titled A Study to Compare Two Paracetamol Formulations. That Phase 1 trial is completed, enrolled 30 participants, was active controlled, and included healthy volunteers aged 18 years and older in the United States.
The Phase 1 trial NCT01592227 compared two paracetamol formulations in pain. It was randomized and active controlled, enrolled 30 participants, and was not double blind. It included healthy volunteers of all sexes aged 18 years and older and was conducted in the United States.